Q-omics provides the consensus-scored CIAO2A profile across patient tissues and cancer cell-line models. CIAO2A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CIAO2A is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, CIAO2A protein abundance shows 22,125 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, HNSC, and PDAC as cancer lineages where CIAO2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CIAO2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CIAO2A survival associations across molecular data types. CIAO2A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CIAO2A RNA expression–survival associations across cancer types. High CIAO2A expression shows unfavorable associations in UVM, LGG, ESCA and LUAD, but favorable associations in UCEC and READ. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for CIAO2A RNA expression.
This table summarizes CIAO2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CIAO2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CIAO2A shows higher tumor expression in HNSC, BLCA, STAD, UCEC, BRCA and ESCA. The HNSC box plot shows higher CIAO2A RNA expression in tumor versus normal tissue (log2 FC = +0.994, t-test p < 0.001).
This table shows molecular features associated with CIAO2A in patient tissues and cancer cell lines. In patient samples, CIAO2A shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, CIAO2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
